Akèy › Leukemi › Kalifòni › Los Angeles
Etid klinik pou Leukemi nan Los Angeles, CA
16 etid pou Leukemi ap chèche patisipan nan sit nan ak bò kote Los Angeles (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Ap rekriteFaz 3
- Quetzal Site 7, Los Angeles
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Ap rekriteFaz 2
- USC Norris Comprehensive Cancer Center, Los Angeles
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Ap rekriteFaz 2
- UCLA Medical Center, Los Angeles
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Children s Hospital of Los Angeles, Los Angeles
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ap rekriteFaz 3
- Cedars-Sinai Medical Center, Los Angeles
- University of California, Los Angeles, Los Angeles
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- USC Norris Comprehensive Cancer Center, Los Angeles
- UCLA Health - Bowyer Oncology Center, Los Angeles
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Ap rekriteFaz 2
- Children's Hospital Los Angeles, Los Angeles
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Ap rekriteFaz 1/2
- Research Site, Los Angeles
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
- Valkyrie Clinical Trials, Los Angeles
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Ap rekriteFaz 1/2
- David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Ap rekriteFaz 2
- UCLA Department of Medicine, Los Angeles
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Ap rekriteFaz 2/3
- Keck School of Medicine of USC, Los Angeles
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Ap rekriteFaz 1/2
- Los Angeles Cancer Network, Los Angeles
- UCLA Medical Center of Hematology/Oncology, Los Angeles
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ap rekriteFaz 1
- USC / Norris Comprehensive Cancer Center, Los Angeles
- UCLA - Bowyer Oncology Center, Los Angeles
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Ap rekriteFaz 1
- University of California Los Angeles, Los Angeles
Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress.
Ap rekriteVolontè an sante akeyi
- Children's Hospital Los Angeles, Los Angeles
Etid Leukemi nan lòt vil
- Houston, TX28 etid
- Boston, MA25 etid
- New York City, NY19 etid
- Chicago, IL16 etid
- Durham, NC13 etid
- Baldwin Park, CA12 etid
- Columbus, OH12 etid
- Nashville, TN12 etid
- Philadelphia, PA12 etid
- Milwaukee, WI11 etid
- Atlanta, GA11 etid
- Seattle, WA11 etid
Lòt etid nan Los Angeles
- Kansè Poumon ki pa ti selil87 etid
- Kansè (tout kalite)73 etid
- Kansè nan tete72 etid
- Kansè pwostat61 etid
- Kansè kolorektal59 etid
- Kansè Metastatik57 etid
- Kansè ovè50 etid
- Kansè poumon45 etid
- Karsinòm selil skuamèz tèt ak kou42 etid
- Kansè pankreyas35 etid
- Kansè Endomèt34 etid
- Melanom34 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.